Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation

Immunotherapy is less effective in non-small cell lung cancer (NSCLC) with driver mutations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) and some may extrapolate this trend to other driver mutations. Up to 4% of NSCLC cases contain a BRAF mutation. Most BRAF mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rittberg, Rebekah, Banerji, Shantanu, Green, Susan, Qing, Gefei, Dawe, David E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704186/
https://www.ncbi.nlm.nih.gov/pubmed/33269152
http://dx.doi.org/10.7759/cureus.11224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704186/
https://www.ncbi.nlm.nih.gov/pubmed/33269152
http://dx.doi.org/10.7759/cureus.11224

Ejemplares similares